Allergan plc Forecasted to Earn FY2022 Earnings of $17.62 Per Share (NYSE:AGN)

Allergan plc (NYSE:AGN) – Investment analysts at SunTrust Banks boosted their FY2022 EPS estimates for Allergan in a report issued on Monday, July 15th. SunTrust Banks analyst G. Gilbert now anticipates that the company will earn $17.62 per share for the year, up from their previous estimate of $17.60. SunTrust Banks currently has a “Buy” rating and a $185.00 target price on the stock.

Allergan (NYSE:AGN) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $3.79 EPS for the quarter, beating analysts’ consensus estimates of $3.55 by $0.24. The company had revenue of $3.60 billion for the quarter, compared to analyst estimates of $3.55 billion. Allergan had a positive return on equity of 8.45% and a negative net margin of 45.94%. The company’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same period last year, the company earned $3.74 earnings per share.

A number of other research analysts have also commented on the company. Goldman Sachs Group set a $27.00 price target on Melco Resorts & Entertainment and gave the company a “buy” rating in a report on Tuesday, May 28th. Svb Leerink reissued a “market perform” rating and set a $188.00 price target (down from $217.00) on shares of Allergan in a report on Thursday. Barclays lowered their price target on from GBX 320 ($4.18) to GBX 290 ($3.79) and set an “overweight” rating on the stock in a report on Tuesday, June 25th. Royal Bank of Canada reaffirmed an “underperform” rating and set a GBX 215 ($2.81) target price on shares of in a report on Wednesday, June 26th. Finally, ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $176.27.

Shares of AGN opened at $163.16 on Thursday. The firm has a market capitalization of $53.48 billion, a price-to-earnings ratio of 9.78, a price-to-earnings-growth ratio of 1.53 and a beta of 1.63. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.71 and a quick ratio of 0.60. Allergan has a one year low of $114.27 and a one year high of $197.00. The company’s fifty day simple moving average is $145.42.

A number of large investors have recently added to or reduced their stakes in AGN. Liberty Wealth Management LLC boosted its position in shares of Allergan by 108.8% in the 1st quarter. Liberty Wealth Management LLC now owns 190 shares of the company’s stock valued at $27,000 after purchasing an additional 99 shares during the period. Legacy Bridge LLC acquired a new position in shares of Allergan in the 1st quarter valued at $27,000. Patriot Financial Group Insurance Agency LLC boosted its position in shares of Allergan by 2,162.5% in the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 181 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares during the period. Investors Research Corp acquired a new position in shares of Allergan in the 1st quarter valued at $29,000. Finally, Evolution Wealth Advisors LLC acquired a new position in shares of Allergan in the 2nd quarter valued at $30,000. 80.08% of the stock is currently owned by hedge funds and other institutional investors.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 13th. Investors of record on Tuesday, August 13th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a yield of 1.81%. Allergan’s payout ratio is currently 17.74%.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Featured Story: Debt-To-Equity Ratio

Earnings History and Estimates for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with's FREE daily email newsletter.